Tanzania

Tanzania is rapidly emerging as a high-growth life sciences ecosystem in East Africa, driven by the government’s Vision 2050 framework for health industrialization.

The nation is best known for its strategic pivot toward domestic pharmaceutical manufacturing, specifically for essential medicines, antiretrovirals (ARVs) and cardiovascular drugs.

With the Tanzania Medicines and Medical Devices Authority (TMDA) maintaining WHO Maturity Level 3, the country offers a globally recognized regulatory environment that ensures high standards for Good Manufacturing Practice (GMP).

Investment is surging into healthcare innovation hubs like the Mloganzila initiative, which fosters medical device assembly, diagnostics and advanced formulation.

In biotechnology, Tanzania is prioritizing the development of a national vaccine research laboratory to bolster local production of TB and cancer vaccines. The academic research sector, led by the National Institute for Medical Research (NIMR), is a regional powerhouse for clinical trials focused on infectious diseases, antimicrobial resistance (AMR) and neglected tropical diseases.

Furthermore, the country’s integration into the African Continental Free Trade Area (AfCFTA) positions it as a vital logistics gateway for life sciences supply chains across the EAC and SADC regions.

International stakeholders are increasingly drawn to Tanzania’s blended finance opportunities and contract manufacturing potential.

As digital health and medical technology gain momentum, Tanzania is solidifying its reputation as a resilient and investable frontier for global life sciences.